Morningstar1mon
Immunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing
such as celiac disease as well as inflammatory bowel disease, Graft-versus-Host-Disease and weight management. IMU-381, which currently is in preclinical testing, is a next generation molecule ...
Yahoo Finance1mon
Immunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing
IMU-856 also showed a dose-dependent reduction of body weight gain and food consumption in preclinical in vivo testing ... Our phase 1b clinical trial in celiac disease patients demonstrated ...
Mena FN1mon
Immunic’S Oral IMU-856 Demonstrated Dose-Dependent Increase Of GLP-1 In Celiac Disease Patients And Corresponding Effects In Preclinical Testing
Immunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac disease Patients and Corresponding Effects in Preclinical Testing – New Data Suggests that IMU-856 Could Be a ...